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ARF = acute renal failure; MAP = mean arterial pressure.
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Septic shock, systemic inflammation (resulting from trauma,
major surgery, cardiopulmonary bypass etc.), or pharmaco-
logical vasodilatation (caused by phosphodiasterase
inhibitors, sedative drugs, epidural or spinal block) are usually
associated with systemic hypotension, despite normal or
increased cardiac output [1]. Under these circumstances,
hypotension may persist despite vigorous volume expansion.
Potent systemic vasopressor agents, such as noradrenaline
or so-called high-dose dopamine can then be used to restore
an acceptable mean arterial blood pressure [2–5]. Under
these conditions, renal dysfunction is common (oliguria
and/or a rising serum creatinine) and the use of noradrenaline
is typically fraught with controversy. In this article, we will
review the evidence on the renal effects of the use of nora-
drenaline in critically ill patients and seek to provide clinicians
with a clinically relevant update aimed at helping them to
make informed decisions in the care of their patients.
Why use vasopressors?
The rationale for vasopressor therapy in hypotensive states is
based on the physiological knowledge that, in all regional cir-
culations, including the renal, splanchnic, cerebral and coro-
nary beds, blood flow is autoregulated. This means that, if
cardiac output is preserved, as long as blood pressure is
maintained at a sufficient value, organ blood flow does not
change. When blood pressure falls below a given value
(autoregulatory threshold), however, such autoregulation is
lost. Then, as blood pressure falls, organ blood flow also
decreases in an almost linear fashion. Decreased blood flow
may induce organ ischemia, which, in turn, may contribute to
organ failure. This decrease in blood flow may be particularly
marked in those patients with critical renal, mesenteric,
carotid or coronary lesions (atheroma, fibroplasia etc.). Fur-
thermore, this fall in blood pressure is likely to occur at a
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Abstract
Septic shock, systemic inflammation and pharmacological vasodilatation are often complicated by
systemic hypotension, despite aggressive fluid resuscitation and an increased cardiac output. If the
physician wishes to restore arterial pressure (>80–85 mmHg), with the aim of sustaining organ
perfusion pressure, the administration of systemic vasopressor agents, such as noradrenaline,
becomes necessary. Because noradrenaline induces vasoconstriction in many vascular beds (visibly in
the skin), however, it may decrease renal and visceral blood flow, impairing visceral organ function. This
unproven fear has stopped clinicians from using noradrenaline more widely. In vasodilated states,
unlike in normal circulatory conditions, however, noradrenaline may actually improve visceral organ
blood flow. Animal studies show that the increased organ perfusion pressures achieved with
noradrenaline improve the glomerular filtration rate and renal blood flow. There are no controlled human
data to define the effects of noradrenaline on the kidney, but many patient series show a positive effect
on glomerular filtration rate and urine output. There is no reason to fear the use of noradrenaline. If it is
used to support a vasodilated circulation with a normal or increased cardiac output, it is likely to be the
kidney’s friend not its foe.
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higher blood pressure value in these patients, as well as in
those with long-standing hypertension. It is also important to
note that different vascular beds will lose autoregulation at
different blood pressure values. For example, the mammalian
kidney appears to do so at a mean arterial pressure (MAP) of
about 80 mmHg, while the brain and coronary circulation
require a MAP of somewhere between 30 and 50 mmHg
(Fig. 1). In addition, the pressure–flow relationship for the
kidney appears to follow a steeper slope than that of other
regional beds. Thus, for a given fall in blood pressure, the pro-
portional fall in blood flow would be expected to be particu-
larly sharp for the kidney.
These physiological observations suggest that the restoration
of blood pressure is a logical and desirable therapeutic goal
in the pursuit of renal protection, particularly if a patient
remains hypotensive and oliguric after adequate fluid resusci-
tation. Unfortunately, the drugs necessary to restore a higher
MAP have properties that raise concerns about their use.
Noradrenaline
Noradrenaline is very effective in raising arterial blood pres-
sure and, under almost all circumstances, can be titrated to
achieve the desired MAP in a given patient. However, since
noradrenaline induces vasoconstriction via α-adrenergic stim-
ulation, it may also decrease organ blood flow, if regional vas-
cular beds constrict in excess. In such a scenario, intra-organ
vascular resistance would increase proportionately more than
perfusion pressure and overall blood flow would decrease,
particularly for the kidney. In fact, noradrenaline infusions
have been reported to decrease splanchnic [6,7] and renal
blood flow [8–10] under normal circulatory conditions, as
well as during essential hypertension and hypovolemic
hypotension. These reports have significantly inhibited the
clinical use of noradrenaline.
The studies that suggest that noradrenaline may induce
splanchnic or renal ischemia, however, are open to several
criticisms. Importantly, they do not address the effects of
noradrenaline in vasodilated, hypotensive states and may not
even accurately reflect the longer-term effect of noradrenaline
infusion in normal subjects. On the other hand, if noradrena-
line infusion induces visceral organ hypoperfusion in the
vasodilated patient, then it could induce multiple organ dys-
function, loss of gut mucosal integrity [11], renal ischemia
and the development of acute renal failure (ARF). In the light
of such considerations, concern continues to exist as to the
advisability of sustained vasopressor infusions in the hypoten-
sive patient.
It is not clear if the hypothetical scenario of vasopressor-
induced renal hypoperfusion actually occurs in sepsis or
other vasodilated states. Such clinical states are character-
ized by profound alterations in vascular tone. Downregulation
of vascular smooth muscle α-adrenergic receptor responsive-
ness [12] and active vasodilatation occur due to massive
nitric oxide release [13]. In addition, microvascular obstruc-
tion by aggregation of platelets and white blood cells, formed
by adhesion to the activated vascular endothelium, can
disrupt local blood flow distribution, independently of α-
adrenergic tone [14]. Finally, increased cAMP concentrations
in the smooth muscle cells of blood vessels, induced by the
administration of phosphodiasterase inhibitors, will also
decrease vessel tone, as would the loss of sympathetic
outflow from epidural blockade.
Under circumstances of marked vasodilatation, it makes
physiological sense to think that the restoration of normal or
near normal vascular tone and adequate renal perfusion pres-
sure should improve renal blood flow and the glomerular filtra-
tion rate. It is controversial, however, whether or not
noradrenaline can achieve these goals safely.
Current knowledge about noradrenaline
It is well known that noradrenaline can be used to induce a
reversible model of ARF [15,16] when infused into the renal
artery. Such ARF is induced by intensive renal vasoconstric-
tion. Once again, such observations make the physician wary
of using noradrenaline in the clinical setting of renal dysfunc-
tion, in case it may induce or contribute to ARF. A more accu-
rate analysis of the available data, however, is warranted.
Noradrenaline-induced intense vasoconstriction has only
been seen to occur with the infusion of the drug directly into
the renal artery not via the systemic route at clinically relevant
doses [15,16]. In addition, the dose of drug used in models
of noradrenaline-induced acute renal failure was twice to
Figure 1
The relationship between perfusion pressure and organ flow for the
kidney and heart under the pathophysiologic conditions of hypertrophy
or renovascular disease. Coronary perfusion pressure = diastolic
arterial pressure - left ventricular end diastolic pressure. Renal
perfusion pressure = mean arterial pressure – tissue pressure.
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three times that used in appropriate animal studies and well
beyond the mean dose usually administered in clinical prac-
tice. The relevance of these investigations to clinical practice
is, at best, negligible.
Schaer and co-workers have also reported the renal effects
of noradrenaline infusion at different doses, with or without
the addition of low-dose dopamine [17]. They measured renal
blood flow with the technique of regional thermodilution (an
unvalidated approach). They found that, although renal vascu-
lar resistance appeared to increase from baseline (there was
no placebo arm), total renal blood flow progressively
increased with increasing doses of intravenous noradrenaline
up to 1.6 µg/kg/minute. In their study, any adverse effects of
noradrenaline infusion on renal vascular resistance (please
note that total renal blood flow actually increased) were seen
in animals with a baseline mean arterial blood pressure of
151 mmHg. No sane clinician would prescribe noradrenaline
to a patient with a mean arterial blood pressure of
150 mmHg! Furthermore, noradrenaline infusion increased
MAP by approximately 30% to 200 mmHg. The relevance of
these data to clinical practice is minimal.
On the other hand, a study by Anderson and co-workers
appears to mimic clinical practice more closely [18]. These
investigators infused noradrenaline intravenously at
0.2–0.4 µg/kg/minute (a clinically relevant dose) in conscious
dogs and, using an electromagnetic flow probe, studied renal
blood flow, renal vascular resistance, and glomerular filtration
rate. They found that renal blood flow increased and renal
vascular resistance decreased in response to short-term
noradrenaline infusion (Fig. 2). Such noradrenaline-induced
renal vasodilatation was unaffected by pretreatment with
indomethacin, propranolol, or angiotensin-converting enzyme
inhibition. Renal vasodilatation, therefore, was not
prostaglandin-mediated and was independent of β-receptor
stimulation or of angiotensin-derived changes in vascular
tone. Efferent autonomic sympathetic nerve blockade with
pentolinium prior to noradrenaline infusion, however, com-
pletely abrogated noradrenaline-induced renal vasodilatation.
These investigators logically concluded that, in keeping with
previous experimental data [19], most of the renal vasodilat-
ing effect of intravenous noradrenaline could be attributed to
an increase in systemic blood pressure, which decreased
renal sympathetic tone through a baroreceptor response,
leading to vasodilatation.
The effect of noradrenaline infusion on regional blood flow in
the dog has also been recently explored by Zhang and co-
workers [20]. These investigators have also demonstrated
that, in the endotoxemic dog, noradrenaline did not induce
any decrease in renal or hepatic blood flow.
The effects of noradrenaline infusion on renal blood flow may
not be unique to this vasopressor, but representative of the
effects of a group of potent vasoconstrictor agents. For
example, Bersten and co-workers have recently studied the
renal effects of adrenaline, another potent vasopressor agent,
with a strong mixed β- and α-adrenergic effect. These investi-
gators administered adrenaline by continuous infusion at clini-
cally relevant doses in normal and septic sheep [21,22]. After
a small decrease in renal blood flow at the highest doses
tested (0.4–0.8 µg/kg/minute), renal blood flow progressively
increased. It remained elevated for up to six hours of nora-
drenaline infusion. A similar increase in renal blood flow
occurred in septic animals.
All of the above studies support the notion that mixed β- and
α-adrenergic agents (noradrenaline affects both receptors),
when given to restore blood pressure during vasodilatation,
will generally improve renal blood flow. The physiological
question persists, however, concerning the effect of nor-
adrenaline per se on the tone of the renal vasculature. Such
analysis demands that effects of noradrenaline on blood pres-
sure should be removed from consideration by statistical
methods and that issues of pre-load should also be elimi-
nated by experimental methods. To address this issue,
Bellomo et al. have recently conducted a complex and highly
invasive physiological study in the dog [23]. While a discus-
sion of the methodology is not warranted here, a few points
should be emphasized. The vascular occlusion technique for
the inferior vena cava was used. Such occlusion induces a
fall in pre-load that allows differences in pre-load between dif-
ferent hemodynamic states to be essentially eliminated from
the assessment of the effect of the drug itself on the renal
vasculature. It should also be noted that both the P/Q
Figure 2
Histogram illustrating the effect of different doses
(0–0.4 µg/kg/minute) of noradrenaline on mean arterial pressure
(MAP), renal blood flow (RBF), renal vascular resistance (RVR) and
glomerular filtration rate (GFR) in the dog. Both MAP and GFR are
significantly increased by noradrenaline at clinically relevant doses.
*P < 0.01; **P < 0.05. Published with permission from The Journal of
Physiology [18].
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Dose:relationship (dynamic resistance) and the point of zero flow
were defined. The point of zero flow represents pre-capillary
sphincter tone. Another point is that these investigators
studied the animal in the septic and normal state with
repeated control observations and a crossover design.
Noradrenaline infusion, at clinically relevant dosages, affected
renal blood flow differentially during basal and acute endotox-
emic conditions. When normal circulatory controls existed in
the otherwise unstressed circulation, noradrenaline infusion
failed to proportionally increase dynamic renal blood flow
despite increasing arterial pressure. By contrast, once the cir-
culation had been perturbed by the insult of acute endotox-
emia (and probably any other state inducing a major degree
of vasodilatation), identical dosages of noradrenaline
increased both dynamic renal blood flow and perfusion pres-
sure. Importantly, the methodology used allowed the investi-
gators to isolate the effect of the intravenous infusion of
noradrenaline on the determinants of steady state renal blood
flow independent of perfusion pressure. Under normal condi-
tions, noradrenaline, infused intravenously at a rate capable of
increasing MAP by approximately 15 mmHg, induced a
decrease in renal vascular ohmic resistance, but an increase
in vascular critical closing pressure. This change was such
that, in the aggregate, these combined renal vasoactive
effects reduced renal blood flow for a constant perfusion
pressure. During acute endotoxemic conditions, however, the
initial state of the renal vasculature was altered, reflecting the
profound effects that endotoxemia has on vascular smooth
muscle tone and vascular responsiveness. Under these con-
ditions, the addition of noradrenaline infusion further
decreased renal vascular ohmic resistance. It also decreased
the vascular critical closing pressure such that, in the aggre-
gate, these combined renal vascular effects served to
increase renal blood flow for a constant perfusion pressure.
Thus, noradrenaline infusion in acute endotoxemia appears to
reverse systemic hypotension and improve renal blood flow
independent of perfusion pressure. These findings, in associ-
ation with other literature cited, provide a physiological basis
for the administration of noradrenaline during septic shock
and other vasodilated states.
Noradrenaline or high-dose dopamine
Studies that directly measure renal blood flow and resistance
in humans are not available. Many clinical reports, however,
support the notion that the continuous infusion of noradrena-
line may increase urine output and improve creatinine clear-
ance in hyperdynamic septic shock [24–30]. Of particular
interest is a study by Martin and co-workers because it is the
only randomized, controlled study available [3]. These investi-
gators randomized 32 patients with hyperdynamic and
hypotensive septic shock to receive either high-dose
dopamine (up to 50 µg/kg/minute) or noradrenaline (up to
1 µg/kg/minute) in order to achieve a predetermined arterial
blood pressure (>80 mmHg). They studied the overall hemo-
dynamic response, as well as lactate level and urinary output
after one and six hours of therapy. They found that high-dose
dopamine failed to restore normotension in one third of
patients, while noradrenaline succeeded in all patients
(Fig. 3). In addition, in those patients whose hypotension
could not be corrected with dopamine, noradrenaline
restored a MAP of >80 mmHg. Urinary output was signifi-
cantly improved from baseline once blood pressure was
increased (Fig. 4). This controlled study strongly suggests
that noradrenaline is superior to high-dose dopamine in
restoring blood pressure in septic vasodilated patients, and
that such correction of blood pressure induces an improve-
Available online http://ccforum.com/content/5/6/294
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Figure 3
The blood pressure effect of high-dose dopamine (25 µg/kg/minute)
compared to noradrenaline (up to 1.5 µg/kg/minute) in patients with
hypotensive hyperdynamic septic shock. Noradrenaline is clearly
superior in restoring mean arterial pressure to normotensive levels. 
For all measurements, P < 0.0001.
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Figure 4
The comparative effects of high-dose dopamine and noradrenaline on
urine output in patients with hyperdynamic hypotensive septic shock
and oliguria. Noradrenaline is clearly superior in restoring urine output.
For all measurements, P < 0.0001.
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Time after therapy (hours)ment in urine output. More recently, Martin also reported on
the outcome of 97 adult patients with septic shock, of whom
57 were treated with noradrenaline [31]. Patients treated with
noradrenaline had a lower mortality than those treated with
other pressor drugs, and noradrenaline use was identified as
a predictor of survival on multivariate logistic regression
analysis. These findings support the argument that noradren-
aline is safe and effective in hypotensive vasodilated states
and that its renal effects under these circumstances are likely
to be beneficial.
Conclusion
The use of noradrenaline in intensive-care-unit patients with
hypotension and evidence of renal dysfunction remains the
subject of much debate and controversy. Although it would
appear that at the time of writing noradrenaline use is seen by
many clinicians as somewhat undesirable in these patients,
the data suggest otherwise. It may indeed be that restoration
of blood pressure with noradrenaline has a nephroprotective
effect and that, in vasodilated states, noradrenaline and the
kidney are more friends than foes. Much work remains to be
done, however, on the renal effects of hemodynamic manipu-
lation with catecholamines before we can make clinical deci-
sions based on level I evidence.
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